Overview

Corporate Presentation

Corporate Presentation - August 2023

Download Presentation

Email Alerts

Register to receive real time alerts

Sign Up

IR Contacts

Get in touch with our IR team

Contact Us

Latest Press Releases
Sep 6, 2023
Trevi Therapeutics to Participate in Upcoming September Events

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for difficult to treat patients with...

Aug 10, 2023
Trevi Therapeutics Announces Second Quarter 2023 Financial Results and Provides Business Update

Plans to initiate three clinical studies in chronic cough indications for later this year remain on track Data from Phase 2 CANAL trial of chronic cough in patients with idiopathic pulmonary...

Aug 3, 2023
Trevi Therapeutics to Report Q2 2023 Financial Results and Provide a Corporate Update on August 10, 2023

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for difficult to treat patients with...

View All Press Releases

Events
2023 Cantor Global Healthcare Conference
Tuesday, September 26, 2023 - Thursday, September 28, 2023

Panel Presentation: Tuesday, September 26th, 2:45 PM ET
Presenter: Jennifer Good, President and CEO

View All Events

We are developing the investigational therapy Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions by targeting the central and peripheral nervous systems.

Our novel oral formulation has the potential to unlock new market opportunities and significantly improve the quality of life of patients who currently have few treatment options.

Explore Our Pipeline